Organoid Science (CEO Jongman Yoo), an innovative organoid-based regenerative therapy company, and Dongguk University Ilsan Hospital (Director Beomseon Kwon) announced that they had jointly signed an ‘Agreement for commercialization of organoid regenerative medicine and training of professional manpower.’
Through this agreement, Organoid Science and Dongguk University Ilsan Hospital plan to cooperate to commercialize biomedical technology in the field of regenerative medicine, focusing on joint research and clinical trials. In addition, various matters to exchange excellent human resources and improve educational capabilities will be carried out by utilizing each other’s technology and information.
Through joint research with Organoid Science, which is about to enter the clinical trial of organoid-based regenerative therapy, and Dongguk University Ilsan Hospital, which is leading the research by holding the International Symposium on Stem Cells and Regenerative Medicine, the synergy effect of the two specialized institutions as well as the field of regenerative medicine are achieved. This is the time when successful performance is expected.
“It is an honor to be able to develop innovative technologies with Dongguk University Ilsan Hospital, which has excellent research capabilities and infrastructure,” said Jongman Yoo, CEO of Organoid Science. “We will work closely together to strengthen our competitiveness through mutual exchanges and further contribute to the development of the biomedical industry.”
Director Kwon Beom-seon of Dongguk University Ilsan Hospital said, “Through this agreement, our hospital will actively and systematically establish a technology development ecosystem in the field of regenerative medicine technology, which is an axis of future promising medical technology, and lead the field of regenerative medicine by realizing feasibility. “I will support you,” he said.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news